PAIB-SO isopropyl

PAIB-SO isopropyl (phenyl 4-(2-oxo-3-isopropylimidazolidin-1-yl)benzenesulfonate) is a synthetic small molecule belonging to the phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) family of antimitotic prodrugs. Developed by researchers at Université Laval, PAIB-SOs were designed to be selectively bioactivated by cytochrome P450 1A1 (CYP1A1) inside breast cancer cells into potent antimitotic agents (PIB-SOs) that disrupt microtubule polymerization. However, structure-activity relationship studies demonstrated that PAIB-SO isopropyl is not successfully metabolized into PIB-SO by CYP1A1, instead undergoing hydroxylation without N-dealkylation. As a result, PAIB-SO isopropyl lacks selectivity toward breast cancer cells and exhibits only moderate, non-selective micromolar antiproliferative activity, leading to the discontinuation of its development in favor of other branched alkyl chain derivatives like isobutyl-bearing PAIB-SOs.

Other names

isopropyl PAIB-SOphenyl 4-(2-oxo-3-isopropylimidazolidin-1-yl)benzenesulfonatephenyl 4-(3-isopropyl-2-oxoimidazolidin-1-yl)benzenesulfonate